HPTN 083: Long-Acting Injectable CAB Superior to Daily Oral TDF/FTC as PrEP in MSM and TGW at High Risk of HIV Infection

July 6-10, 2020; Virtual
Long-acting CAB injected intramuscularly every 2 months reduced the risk of HIV infection by 66% compared with daily oral TDF/FTC in high-risk MSM and transgender women.
Format: Microsoft PowerPoint (.ppt)
File Size: 294 KB
Released: July 11, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences
ViiV Healthcare
Merck Sharp & Dohme Corp.

Related Content

From Clinical Care Options (CCO), the use of HIV-ASSIST to support ART selection for a patient who seroconverted after intermittent adherence to PrEP

person default Matthew M. Hamill, MBChB, MPH, MSc, PhD Released: April 22, 2021

CCO commentary by Professor Don Smith on CROI 2021 data on ARV-associated weight gain and long-acting injectable ART

person default Don Smith, MD Released: April 20, 2021

Download CCO slides reviewing data and guidelines on next-line ART for heavily-treatment experienced patients with HIV and multiclass drug resistance

Joseph J. Eron, Jr., MD Monica Gandhi, MD, MPH Released: April 19, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue